BackCitius Pharmaceuticals- Warrants(02/08/2022) Overview

Citius Pharmaceuticals- Warrants(02/08/2022) Net Tangible Assets

Citius Pharmaceuticals- Warrants(02/08/2022)'s net tangible assets is $69M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$69.08M

Peer average / median

Loading

Citius Pharmaceuticals- Warrants(02/08/2022) Net Tangible Assets History

Loading

Citius Pharmaceuticals- Warrants(02/08/2022) vs. peers: Net Tangible Assets Comparison

Loading

Citius Pharmaceuticals- Warrants(02/08/2022) Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Citius Pharmaceuticals- Warrants(02/08/2022) (CTXRW) FAQ

As of the most recent data (March 2026), CTXRW shows a net tangible assets of $69M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTXRW's net tangible assets is now $69M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Citius Pharmaceuticals- Warrants(02/08/2022) is outperforming or lagging.

Tracking CTXRW's net tangible assets over time shows whether Citius Pharmaceuticals- Warrants(02/08/2022) is scaling, shrinking, or reshaping that part of the business. The current reading is $69M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Citius Pharmaceuticals- Warrants(02/08/2022)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $69M) with ownership activity and broader fundamentals.

Citius Pharmaceuticals- Warrants(02/08/2022)'s net tangible assets is $69M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.